28 April 2017
News and Views
Links and Services
This month's issue of the Alimentary Pharmacology & Therapeutics investigates the safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease.
Long-acting lanreotide 120 mg every 4 weeks reduces liver volume in patients with polycystic live
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors